Inflammatory bowel disease was associated with an increased risk for melanoma, regardless of biologic therapy use, according to recent study results.
Researchers used a systematic bibliographic database search through March 2013. The analysis included 12 cohort studies reporting incident melanoma following diagnosis of inflammatory bowel disease (IBD). The random-effects model calculated pooled relative risk.
The studies included 172,837 patients with IBD, with 179 cases of melanoma reported from 1940 to 1979. Melanoma in patients with IBD had a pooled crude incidence rate of 27.5 cases per 100,000 person-years (95% CI, 19.9-37). Overall, across 12 IBD studies, there was an increased relative risk for melanoma of 1.37 (95% CI, 1.10-1.70). The risk rose to 80% among patients with Crohn’s disease (7 studies; RR=1.80; 95% CI, 1.17-2.75), and patients in seven studies with ulcerative colitis had an RR of 1.23 (95% CI, 1.01-1.50).
In studies predating 1998 and before patients were treated with biologics, the risk for melanoma was greater (eight studies; RR=1.52; 95% CI, 1.02-2.25) compared with studies performed after 1998 (two studies; RR=1.08; 95% CI, 0.59-1.96).
“Inflammatory bowel disease is associated with a modest increase in the risk of melanoma, regardless of therapy,” researcher Siddharth Singh, MBBS, a gastroenterologist at Mayo Clinic, Rochester, Minn., told Healio.com. “It is unclear whether individual medications, like anti-[tumor necrosis factor] agents or thiopurines significantly modify this risk of melanoma. Sun-protective measures and an annual skin exam should be recommended for all patients with IBD.”
Disclosure: Researcher Edward V. Loftus Jr., MD, has consulted for and received research support from Janssen Biotech, Abbott Laboratories and UCB Pharma.